Return on Innovation

Global health R&D delivers for Louisiana

US government (USG) investment in global health R&D has delivered

$86.8 million

to Louisiana research institutions

1,200 +

new jobs

for Louisiana

Louisiana’s top global health R&D institutions by USG funding

ORGANIZATION
Tulane University of Louisiana
Louisiana State University and A&M College
National Hansen’s Disease Program
Loyola University New Orleans
Southern University at Shreveport

FUNDING
$61.6 million
$20.1 million
$4.9 million
$215 thousand
$9 thousand

Global health R&D at work in the Pelican State

Researchers from Tulane University and Louisiana State University have helped discover a possible explanation for the rapid spread of Ebola. The team found that a compound known as the “delta peptide” is produced in large amounts in Ebola patients. The investigators theorize that it may be a specific type of viral protein that damages host cells by making their membranes become permeable; in the case of Ebola, this contributes to severe vomiting, internal bleeding, and extreme gastrointestinal distress in patients—in turn contributing to the virus’ spread. The discovery could lead to new treatments for this deadly and highly contagious disease.

Neglected diseases in Louisiana

<table>
<thead>
<tr>
<th>Disease</th>
<th>Louisiana Infections</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV diagnoses</td>
<td>10,216</td>
</tr>
<tr>
<td>Tuberculosis cases</td>
<td>1,442</td>
</tr>
<tr>
<td>West Nile cases</td>
<td>685</td>
</tr>
<tr>
<td>Malaria cases</td>
<td>73</td>
</tr>
<tr>
<td>Zika cases</td>
<td>39</td>
</tr>
</tbody>
</table>

Louisiana’s top areas of global health R&D by USG funding

- Tuberculosis: 28.7%
- HIV/AIDS: 28%
- Malaria: 13.7%
- NTDs: 13.7%†
- Ebola/VHFs: 5.3%‡
- Diarrheal diseases: 3.7%
- Other: 7%

GLOBAL HEALTH R&D IS A SMART INVESTMENT FOR THE UNITED STATES

89¢ of every dollar

the USG invests in global health R&D stays within the United States, supporting the domestic economy.

USG investment in global health R&D between 2007 and 2015 generated an estimated:

200K new US jobs

$33 BILLION in US economic growth.

† Authors’ analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007-2015 and for Ebola and select viral hemorrhagic fevers from 2014-2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See www.ghtcoalition.org for full methodology.

‡ Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author’s analysis described above. See www.ghtcoalition.org for additional details.


¶ National Institutes of Health R&D funding and author’s analysis described above. See www.ghtcoalition.org for additional details.


NTD: neglected tropical disease, VHF: viral hemorrhagic fever. NTDs include Buruli ulcer, Dengue, Helminths, Kinetoplastids, Leprosy, Trachoma, and Leptospirosis.

www.ghtcoalition.org